Alexei A Grom MD
Associate Professor, Pediatrics, University of Cincinnati College of Medicine
Join to View Full Profile
3333 Burnet AveMl 4010Cincinnati, OH 45229
Phone+1 513-636-7686
Fax+1 513-636-5568
Dr. Grom is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Cincinnati Children's Hospital Medical CenterResidency, Pediatrics, 1997 - 1998
St Petersburg Medical State AcademyClass of 1986
Certifications & Licensure
OH State Medical License 1999 - 2027
KY State Medical License 2021 - 2026
IN State Medical License 2021 - 2023
American Board of Pediatrics Pediatric Rheumatology
Awards, Honors, & Recognition
- Fellow American College of Rheumatology
Publications & Presentations
PubMed
- 1 citationsClinical, Immunologic, and Genetic Characteristics in Patients With Syndrome of Undifferentiated Recurrent Fevers.Marci Macaraeg, Elizabeth Baker, Elizabeth Handorf, Michael Matt, Elizabeth K Baker
Arthritis & Rheumatology. 2025-05-01 - 1 citationsAllogeneic haematopoietic stem-cell transplantation for children with refractory systemic juvenile idiopathic arthritis and associated lung disease: outcomes from an i...Michael G Matt, Daniel Drozdov, Elisabeth Bendstrup, Mia Glerup, Ellen-Margrethe Hauge
The Lancet. Rheumatology. 2025-04-01 - Transcriptional Profiling of Tofacitinib Treatment in Juvenile Idiopathic Arthritis: Implications for Treatment Response Prediction.Esraa Eloseily, Alex Pickering, Sanjeev Dhakal, Nicolino Ruperto, Hermine I Brunner
Arthritis Care & Research. 2025-04-01
Other
- Juvenile idiopathic arthritis: Epidemiology and immunopathogenesisGrom AA
http://www.uptodate.com/contents/juvenile-idiopathic-arthritis-epidemiology-and-immunopathogenesis
UpToDate, Wolters Kluwer Health - 2012-10-31
Press Mentions
FDA Approves First Treatment for Macrophage Activation Syndrome in Still DiseaseJune 30th, 2025
FDA Approves Gamifant (Emapalumab-Lzsg) as First-Ever Treatment for Adults and Children with Macrophage Activation Syndrome in Still's DiseaseJune 28th, 2025
Emapalumab Rapidly Controls MAS in Patients with Still’s DiseaseDecember 16th, 2024- Join now to see all
Grant Support
- CINCINNATI TRAINING PROGRAM IN PEDIATRIC RHEUMATOLOGYRESEARCHCINCINNATI CHILDRENS HOSP MED CTR2016–2025
- CINCINNATI TRAINING PROGRAM IN PEDIATRIC RHEUMATOLOGYRESEARCHCINCINNATI CHILDRENS HOSP MED CTR2016–2025
- Pathobiology Of The Monomyelocytoid Cell Gene Expression Signature In SystemicjiaNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2011
- MUNC13-4 Gene Polymorphisms In Macrophage Activation Syndrome And Systemic JuveniNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2011
- Macrophage Activation Syndrome Biomarkers In Systemic Juvenile Idiopathic ARTNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2010–2011
- Macrophage Activation Syndrome Biomarkers In Systemic Juvenile Idiopathic ARTNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2008–2009
- Gene Expression Profiles In Systemic Onset Juvenile Rheumatoid Arthritis...National Institute Of Arthritis And Musculoskeletal And Skin Diseases2007
- Pathogenic Mechanisms Of The Vasculopathy Of JDMNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2003–2004
- IL15 And Vascular Endothelial Activation In JRA SynoviumNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2001–2002
- Tumor Necrosis Factor In Juvenile Rheumatoid ArthritisNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1994
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
